Hybrid Microcapsules Containing Islets and Anti-Inflammatory Drugs for Diabetes Therapy

Exclusively Licensed

A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Researchers

Robert Langer / Joshua Cohen / Karolina Siniakowicz / Jennifer Hollister-Lock / Thuy Dang / Gordon Weir / Daniel Anderson

Departments: Office of the Institute Professors, Department of Chemical Engineering
Technology Areas: Biomaterials & Bioelectronics: Tissue Repair / Therapeutics: Cell Based Therapy, Proteins & Antibodies, Regenerative Medicine
Impact Areas: Healthy Living

  • hydrogel encapsulated cell and anti-inflammatory drugs
    United States of America | Granted | 10,709,667
  • hydrogel encapsulated cells and anti-inflammatory drugs
    United States of America | Granted | 9,867,781
  • hydrogel encapsulated cells and anti-inflammatory drugs
    United States of America | Granted | 10,278,922

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies